Home / Precision Medicine (page 29)

Precision Medicine

ImmunoGen Licenses ADC Technology to Takeda for Development of Cancer Drugs

Oncology biotech ImmunoGen, Inc. announced that it has entered into a $440 million antibody-drug conjugate (ADC) licensing deal with Takeda Pharmaceutical Company Limited. Takeda has licensed exclusive rights to use ImmunoGen’s ADC technology to develop and commercialize targeted anticancer therapeutics to up to two undisclosed targets. Under the deal, ImmunoGen …

Read More »

Amicus to Seek Accelerated US and European Approval of its Investigational Fabry Disease Drug

Amicus Therapeutics announced its plans to file for accelerated approval of its investigational drug for a rare, inherited disease, following meetings with regulators in the US and Europe. The company said that it has recently met with regulatory authorities in Europe and the US to discuss the approval pathways for …

Read More »

Vaccinex Enters Deal with Five Prime Therapeutics Utilizing Vaccinex’s Antibody Discovery Platform

Privately-held clinical-stage immunotherapy company, Vaccinex, Inc., recently announced that it has signed a multi-target antibody discovery deal with Five Prime Therapeutics. Vaccinex said that it has entered into a multi-target collaboration agreement with Five Prime to utilize Vaccinex’s ActivMab antibody discovery platform for the discovery of monoclonal antibodies against novel …

Read More »

Myriad Expands Collaboration with BioMarin for Cancer Companion Diagnostic Test

Myriad Genetics recently announced that it has expanded its collaboration with BioMarin Pharmaceutical to use Myriad’s myChoice HRD companion diagnostic test. Under the deal, BioMarin will use Myriad’s myChoice HRD companion diagnostic test to prospectively identify patients with metastatic breast, ovarian and potentially other tumor types that may be sensitive …

Read More »

Genmab Acquires Targeted Antibodies from iDD Biotech, While Opting out of its Co-Development Option with ADC Therapeutics

Genmab A/s is altering its pipeline, announcing that the company has agreed to acquire three pre-clinical stage targeted antibodies from iDD Biotech and the company’s decision to drop the option to co-develop HuMax-TAC-ADC with ADC Therapeutics Sarl. Genmab said that it has entered into an agreement to purchase antibodies and …

Read More »

Ignyta Advances its Precision Oncology Vision with its Acquisition of Four Targeted Cancer Programs from Teva

Precision oncology biotech Ignyta has acquired worldwide rights and assets relating to four targeted oncology development programs from Teva Pharmaceutical Industries. The companies announced that Ignyta will acquire four oncology assets from Teva in exchange for 1.5 million shares, or six percent of Ignyta’s common stock. Concurrently, Ignyta has entered …

Read More »

FDA Approves Expanded Age Range for Vertex’s Kalydeco

Vertex Pharmaceuticals’ cystic fibrosis (CF) drug is now approved in the US for an expanded group of patients. The company announced that the US Food and Drug Administration (FDA) has approved Kalydeco (ivacaftor) for use in children ages 2-5 with CF who have one of 10 mutations in the cystic …

Read More »

European Commission Approves Novartis’ Jakavi for Treatment of Patients with a Rare Blood Cancer

Today, Novartis announced that the European Commission (EC) has approved Jakavi (ruxolitinib) for the treatment of patients with a rare blood cancer. The company said that the drug is now approved in Europe for the treatment of adults with polycythemia vera (PV) who are resistant to or intolerant of hydroxyurea. …

Read More »

Genetic Test Maker 23andMe Hires Biotech Executive to Lead its Drug Development Effort

Google-backed genetic-testing company 23andMe is launching its own drug development unit, and bringing on former Genentech executive to become its chief scientist and lead the company’s research and development efforts. 23andMe has collected genetic information from more than 850,000 customers worldwide from its $99 DNA spit test and more than …

Read More »

Biodesix to Collaborate with Inivata for NGS-Based Lung Cancer Tests

Molecular diagnostics company Biodesix, Inc. is teaming up with clinical cancer genomics company Inivata to develop Next Generation Sequencing (NGS)-blood based tests for lung cancer. The companies announced their partnership to develop and commercialize these tests for clinical applications in lung cancer, leveraging Inivata’s proprietary, enhanced Tam-Seq technology platform and …

Read More »